

**HEPATOBIILIARY CANCERS:
Pathobiology and Translational Advances**

Evaluation Form

1. Poor 2. Fair 3. Good 4. Very Good 5. Outstanding

Circle One

- | | | | | | |
|--|----------|----------|----------|----------|----------|
| a. Conference Organization and Scientific Content: | 1 | 2 | 3 | 4 | 5 |
| b. Quality of Scientific Sessions | | | | | |
| SESSION 1: Hepatobiliary Cancer Risk Conditions and Prevention Strategies | 1 | 2 | 3 | 4 | 5 |
| SESSION 2: Molecular Signaling Pathways, Pathogenesis, and Hepatic Oncogenesis | 1 | 2 | 3 | 4 | 5 |
| SESSION 3: Microenvironment and Hepatobiliary Cancer Progression | 1 | 2 | 3 | 4 | 5 |
| SESSION 4: MicroRNAs in Hepatobiliary Cancer Growth, Progression, and Therapy | 1 | 2 | 3 | 4 | 5 |
| SESSION 5: Genomics and Personalized Medicine for Primary Liver Cancers | 1 | 2 | 3 | 4 | 5 |
| SESSION 6: Molecular Therapeutic Targeting of Hepatocellular and
Cholangiocellular Carcinomas | 1 | 2 | 3 | 4 | 5 |
| c. Timeliness and Overall Significance | 1 | 2 | 3 | 4 | 5 |
| d. Early Investigator Poster Session | 1 | 2 | 3 | 4 | 5 |
| e. Usefulness to Your Own Research | 1 | 2 | 3 | 4 | 5 |
| f. Opportunities for Informal Discussions
and Social Interactions | 1 | 2 | 3 | 4 | 5 |
| g. Representation of Early Career
Investigators | 1 | 2 | 3 | 4 | 5 |
| h. Women and Minorities Representation | 1 | 2 | 3 | 4 | 5 |
| i. Conference Hotel | 1 | 2 | 3 | 4 | 5 |

Would You Like to See This Conference Continued in Future Years?

Yes_____ No_____.

COMMENTS: (Name-Optional, _____)